Anti-PD-1 Therapy plus Chemotherapy and/or Bevacizumab as Second Line or later Treatment for Patients with Advanced Non-Small Cell Lung Cancer
Anti-PD-1 Therapy plus Chemotherapy and/or Bevacizumab as Second Line or later Treatment for Patients with Advanced Non-Small Cell Lung Cancer
复制标题
抗 PD-1 疗法联合化疗和/或贝伐珠单抗作为晚期非小细胞肺癌患者的二线或后续治疗
DOI：
10.7150/jca.37966
复制
发表时间：
2020-01
影响因子：
3.9
通讯作者：
Hu Yi
中科院分区：
文献类型：
--
作者：
Zhang Fan;Huang Di;Li Tao;Zhang Sujie;Wang Jinliang;Zhang Yuzi;Wang Guoqiang;Zhao Zhengyi;Ma Junxun;Wang Lijie;Sun Danyang;Cui Pengfei;Cai Shangli;Jiao Shunchang;Zhao Lei;Hu Yi
免疫检查点抑制剂联合治疗在晚期非小细胞肺癌(ANSCLC)患者的一线治疗中显示出显著的疗效。然而，PD-1抑制剂联合治疗在二线或以后的环境中是否有效仍是未知的。因此，我们回顾评估了PD-1抑制剂联合化疗和/或贝伐单抗与PD-1抑制剂单独治疗二线或以后的非小细胞肺癌患者的疗效。筛选2015至2017年间接受抗PD-1治疗的aNSCLC患者，最终纳入55名患者，并将其分为单一治疗组(N=33)和联合组(N=22)。接受联合治疗的患者比接受单一治疗的患者表现出更好的PFS(中位数PFS，7.5月对3.3月；风险比0.28；95%CI，0.14-0.56；P<；0.001)。客观有效率和疾病控制率联合组分别为31.8%(7/22)和10.0%(3/30)，疾病控制率分别为95.5%(21/22)和10.0%(14/30)(P=0.075；DCR，P<；0.001)。联合治疗组有5名患者(22.7%)出现3-4级不良反应，单一治疗组有2名患者(6.1%)。综上所述，我们的结果表明，对于一线或以后治疗失败的非小细胞肺癌患者，PD-1抑制剂联合化疗和/或贝伐单抗可能是一种有利的治疗方案。这些发现值得在前瞻性研究中进一步验证。
Immune checkpoint inhibitor combination therapy exhibited outstanding efficacy in first line setting for advanced non-small cell lung cancer (aNSCLC) patients. However, whether PD-1 inhibitor combined treatment is effective in second line or later setting remains unknown. Therefore, we retrospectively evaluated the efficacy of combined therapy of PD-1 inhibitor with chemotherapy and/or bevacizumab compared to PD-1 inhibitor alone for aNSCLC patients in second line or later setting. Patients with aNSCLC who have received anti-PD-1 based therapy between 2015 and 2017 were screened, and 55 patients were ultimately included and divided into the monotherapy group (N=33) and the combination group (N=22). Patients treated with combination therapy exhibited superior PFS versus those treated with monotherapy (median PFS, 7.5 months vs 3.3 months; hazard ratio 0.28; 95% CI, 0.14-0.56; P<0.001). Objective response rate and disease control rate were 31.8% (7/22) and 95.5% (21/22) in the combination group and 10.0% (3/30) and 46.7% (14/30) in the monotherapy group, respectively (ORR, P=0.075; DCR, P<0.001). Five patients (22.7%) experienced grade 3-4 adverse events in the combination group and two patients (6.1%) in the monotherapy group. Taken together, our results indicated that for NSCLC patients who had failed on the first-line or later treatment, PD-1 inhibitor in combination with chemotherapy and/or bevacizumab might be a favorable treatment option. These findings warrant further validation in prospective studies.
登录
查看更多内容
影响因子：
5.6
作者：
Pircher A;Wolf D;Heidenreich A;Hilbe W;Pichler R;Heidegger I
通讯作者：
Heidegger I
影响因子：
8.8
作者：
通讯作者：
--
影响因子：
10.1
作者：
Hodi FS;Lawrence D;Lezcano C;Wu X;Zhou J;Sasada T;Zeng W;Giobbie-Hurder A;Atkins MB;Ibrahim N;Friedlander P;Flaherty KT;Murphy GF;Rodig S;Velazquez EF;Mihm MC Jr;Russell S;DiPiro PJ;Yap JT;Ramaiya N;Van den Abbeele AD;Gargano M;McDermott D
通讯作者：
McDermott D
DOI：
10.1158/1078-0432.ccr-15-3101
发表时间：
2016-09-15
期刊：
Clinical cancer research : an official journal of the American Association for Cancer Research
影响因子：
--
作者：
Gainor JF;Shaw AT;Sequist LV;Fu X;Azzoli CG;Piotrowska Z;Huynh TG;Zhao L;Fulton L;Schultz KR;Howe E;Farago AF;Sullivan RJ;Stone JR;Digumarthy S;Moran T;Hata AN;Yagi Y;Yeap BY;Engelman JA;Mino-Kenudson M
通讯作者：
Mino-Kenudson M
影响因子：
45.3
作者：
Rizvi, Naiyer A.;Hellmann, Matthew D.;Antonia, Scott
通讯作者：
Antonia, Scott